The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry

During the process of HIV-1 fusion with the target cell, the N-terminal heptad repeat (NHR) of gp41 interacts with the C-terminal heptad repeat (CHR) to form fusogenic six-helix bundle (6-HB) core. We previously identified a crucial residue for 6-HB formation and virus entry - Lys63 (K63) in the C-terminal region of NHR (aa 54–70), which forms a hydrophobic cavity. It can form an important salt bridge with Asp121 (D121) in gp41 CHR. Here, we found another important conserved residue for virus fusion and entry, Arg46 (R46), in the N-terminal region of NHR (aa 35–53), which forms a hydrogen bond with a polar residue, Asn43 (N43), in NHR, as a part of the hydrogen-bond network. R46 can also form a salt bridge with a negatively charged residue, Glu137 (E137), in gp41 CHR. Substitution of R46 with the hydrophobic residue Ala (R46A) or the negatively charged residue Glu (R46E) resulted in disruption of the hydrogen bond network, breakage of the salt bridge and reduction of 6-HB’s stability, leading to impairment of viral fusion and decreased inhibition of N36, an NHR peptide. Similarly, CHR peptide C34 with substitution of E137 for Ala (E137A) or Arg (E137R) also exhibited reduced inhibitory activity against HIV-1 infection and HIV-1-mediated cell-to-cell fusion. These results suggest that the positively charged residue R46 and its hydrogen bond network, together with the salt bridge between R46 and E137, are important for viral fusion and entry and may therefore serve as a target for designing novel HIV fusion/entry inhibitors.

[1]  Lijun Rong,et al.  Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. , 2010, Biochemistry.

[2]  M. Gochin,et al.  The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. , 2009, Journal of medicinal chemistry.

[3]  Hong Lu,et al.  Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains , 2009, Journal of Virology.

[4]  A. Debnath,et al.  Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain Is Critical for Six-helix Bundle Stability and Virus Entry* , 2007, Journal of Biological Chemistry.

[5]  Shibo Jiang,et al.  HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains , 2007, Journal of Biological Chemistry.

[6]  Yong-tang Zheng,et al.  Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro , 2005, Acta Pharmacologica Sinica.

[7]  Michael D. Miller,et al.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Chan,et al.  The Fusion Activity of HIV-1 gp41 Depends on Interhelical Interactions* , 2005, Journal of Biological Chemistry.

[9]  Shibo Jiang,et al.  Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120* , 2005, Journal of Biological Chemistry.

[10]  A. Debnath,et al.  N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion , 2004, Antimicrobial Agents and Chemotherapy.

[11]  Yuxian He,et al.  Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. , 2003, Vaccine.

[12]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[13]  Min Lu,et al.  Genetic Evidence that Interhelical Packing Interactions in the gp41 Core Are Critical for Transition of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein to the Fusion-Active State , 2002, Journal of Virology.

[14]  Min Lu,et al.  Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. , 2002, Biochemistry.

[15]  Min Lu,et al.  Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis , 2001, Journal of Virology.

[16]  J. Liu,et al.  Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion. , 2001, Biochemistry.

[17]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[18]  C. Weiss,et al.  Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41 , 2000, Journal of Virology.

[19]  D. Chang,et al.  A helix initiation motif, XLLRA, is stabilized by hydrogen bond, hydrophobic and van der Waals interactions. , 2000, Biochimica et biophysica acta.

[20]  J. Liu,et al.  Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. , 1999, Biochemistry.

[21]  Min Lu,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion , 1999, Journal of Virology.

[22]  Q. Sattentau,et al.  Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.

[23]  C. Weiss,et al.  Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41 , 1998, Journal of Virology.

[24]  P S Kim,et al.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[26]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[27]  D. Dimitrov.  How Do Viruses Enter Cells? The HIV Coreceptors Teach Us a Lesson of Complexity , 1997, Cell.

[28]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Weissenhorn,et al.  Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[31]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[32]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[33]  E. Freed,et al.  The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*) , 1995, The Journal of Biological Chemistry.

[34]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[35]  G. Salitra,et al.  Nested fullerene-like structures , 1993, Nature.

[36]  J. Sodroski,et al.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.

[37]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.